Financials data is unavailable for this security.
View more
Year on year Akebia Therapeutics Inc has grown net income from a loss of -94.23m to a smaller loss of -51.93m despite falling revenues.
Gross margin | 82.59% |
---|---|
Net profit margin | -23.18% |
Operating margin | -20.54% |
Return on assets | -17.07% |
---|---|
Return on equity | -- |
Return on investment | -29.47% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Akebia Therapeutics Inc fell by 48.59m. However, Cash Flow from Investing was flat, indicating that little new money was committed to growth. In addition the company used 23.38m for operations while cash used for financing totalled 25.21m.
Cash flow per share | -0.0144 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.1608 |
---|---|
Tangible book value per share | -0.5279 |
More ▼
Balance sheet in USDView more
Current ratio | 1.04 |
---|---|
Quick ratio | 0.8222 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 8.89 |
More ▼